Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Vectibix identification trial published by Amgen

Vectibix identification trial published by Amgen

6th March 2008

The first results from a phase III clinical trial investigating the link between an antibody and a gene found in tumours have been published by Amgen.

The biomarker analysis of the 408 trial was revealed in the Journal of Clinical Oncology and showed that KRAS mutations can help to identify those whose metastatic colorectal cancer will be unresponsive to the first totally human anti-epidermal growth factor receptor monoclonal antibody (EGFr), Vectibix (panitumumab).

Amgen stated that the randomised, controlled trial met both primary and secondary endpoints by showing that the effect of Vectibix monotherapy on progression-free survival varied depending on the status of mutation of the KRAS gene within the tumour.

It was found that response rates affected by Vectibix were limited to patients whose tumours did not contain a mutated version of KRAS.

Dr Roger M Perlmutter, executive vice-president of Amgen’s research and development division, said the KRAS oncogene was a valuable tool in assessing the appropriateness of Vectibix, which was first approved in 2006.

Vectibix is a single agent but no data currently exists to show its effectiveness in increasing survival rates or improving disease-related symptoms.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.